Parkinson's Disease
Conditions
Brief summary
An Open-Label Study in Healthy Male and Female Subjects to Identify the Concentration that Provides Optimal Bioavailability of Levodopa Infused Subcutaneously via a Pump System; and to Compare the Bioavailability of Levodopa/Carbidopa Solution to that of Levodopa/Carbidopa Intestinal Gel (LCIG), Infused via a Naso-Jejunal Tube
Detailed description
Part 1: This is a single centre, open-label design with 2 study arms (ND0612H and ND0612L), in 24 subjects that will receive the ND0612L or ND0612H regimens. Part of the subjects will also participate in Part 2 of the study. Within each study arm, subjects will receive 3 doses of the investigational LD/CD solution for subcutaneous (SC) infusion. Study drug will be administered for 24 -30 hours as a subcutaneous (SC) infusion to the lower abdomen. Then subjects will be readmitted for Part 2. Part 2: This is a single centre, open-label design with 3 treatment arms to which 15 subjects who completed the ND0612H arm of Part 1 ND0612-005a will be allocated in a randomised manner. Within each treatment arm subjects will receive 2 out of 3 doses of LCIG infused for 16 hours directly to the jejunum. Subjects will be discharged from the clinic 24 hours after the end of the last infusion
Interventions
DRUGND0612
Subcutaneous solution
DRUGLCIG
Intrajejunal Gel
Sponsors
Quotient Clinical
NeuroDerm Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion Criteria: Part 1 ND0612-005a: 1. Healthy males or non-pregnant, non-lactating healthy females 2. Age 40 to 65 years of age 3. Body mass index of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator 4. Must be willing and able to communicate and participate in the whole study (Part 1 only for subjects assigned to ND0612L and Part 1 and Part 2 for subjects assigned to ND0612H) 5. Must provide written informed consent 6. Area of administration to be evaluable for local skin reaction (normal skin without skin burns, scars or large tattoos in the area of administration) 7. Must agree to use an adequate method of contraception Inclusion Criteria: Part 2 ND0612-005b: 1\. Subjects who were dosed with ND0612H (any replacements subjects enrolled in Part 2 will be dosed with the optimal LD/CD concentration of ND0612H after completion of Part 2).
Exclusion criteria
1. Participation in a clinical research study within the previous 3 months 2. Subjects who are study site employees, or immediate family members of a study site or sponsor employee 3. Subjects who have previously been enrolled in this study 4. History of any drug or alcohol abuse in the past 2 years 5. Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine) 6. Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening 7. Females of childbearing potential who are pregnant or lactating (female subjects must have a negative urine pregnancy test at admission) 8. Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in Appendix 1) 9. Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1) 10. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results 11. Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening 12. History of cardiovascular, renal, hepatic, chronic respiratory or GI disease as judged by the investigator 13. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients 14. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active 15. Donation or loss of greater than 400 mL of blood within the previous 3 months 16. Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol, hormone replacement therapy and hormonal contraception) or herbal remedies in the 14 days before IMP administration (See Section 11.4). Exceptions may apply on a case by case basis if considered not to interfere with the objectives of the study as agreed by the PI and sponsor's medical monitor 17. Use of any non-selective monoamine oxidase (MAO) inhibitors within 2 weeks of screening 18. History or presence of glaucoma 19. History or presence of suspicious undiagnosed skin lesions or a history of melanoma 20. Any history of psychoses or seizure 21. Known hypersensitivity to Sinemet® or domperidone or any of the excipients 22. Any history or presence of Prolactin-releasing pituitary tumour (prolactinoma) 23. Any medical history of GI haemorrhage, mechanical obstruction or perforation 24. Any history of moderate or severe hepatic impairment 25. Subjects with clinically significant liver function tests 26. Subjects with QTc \>450 ms at screening 27. Subjects with significant electrolyte disturbances 28. Subjects with any underlying cardiac disease 29. Subjects who have received QT-prolonging drugs or potent cytochrome P450 (CYP) 3A4 inhibitors within 4 weeks of screening 30. ND0612H arm only: Subjects who have sinus problems 31. ND0612H arm only: Subjects who have regular heartburn and/or indigestion 32. ND0612H arm only: Subjects who have had abdominal (bowel) surgery 33. ND0612H arm only: Any clinically significant findings observed during naso-jejunal tube placement as determined by the endoscopist 34. Failure to satisfy the investigator of fitness to participate for any other reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax (maximal plasma concentration) of CD for different doses of CD | 6 days | Pre-infusion and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 17, 20, 22, 24, 25, 26, 27, 28, 29, 30, 31, and 32 hours after commencing the ND0612 infusion on Days 1, 3 and 5. |
| AUC (area under the curve) of CD for different doses of CD | 6 days | Pre-infusion and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 17, 20, 22, 24, 25, 26, 27, 28, 29, 30, 31, and 32 hours after commencing the ND0612 infusion on Days 1, 3 and 5. |
| Cmax (maximal plasma concentration) of LD and CD for ND0612 vs. LCIG | 4 days | Pre-infusion and at 1, 2, 3, 4, 6, 9, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours after commencing the LCIG infusion on Days 1 and 3. |
| AUC (area under the curve) of LD and CD for ND0612. LCIG | 4 days | Pre-infusion and at 1, 2, 3, 4, 6, 9, 12, 14, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours after commencing the LCIG infusion on Days 1 and 3. |
Countries
United Kingdom
Outcome results
None listed